Efficacy of secukinumab compared to ustekinumab in mod/seve psoriasis.

• Research type

  Research Study

• Full title

  A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis

• IRAS ID

  141917

• Contact name

  Benjamin Walker

• Contact email

  benjamin.walker@hdft.nhs.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2013-003434-32

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  14/EM/0032

• Date of REC Opinion

  27 Feb 2014

• REC opinion

  Further Information Favourable Opinion